Total Funding
49
64
Total FundingSeries B raised
Growth Score
-4 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
12215
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
- Lisa Fiering: SVP, People and Culture
- Michael Gray: Chief Financial Officer and Chief Operating OfficerPast Role: Carmot Therapeutics, Chief Financial and Chief Operating Offer
Upstream Bio
About the Company
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. They are clinical-stage monoclonal antibodies that inhibit the TSLP receptor, a validated target located upstream of various signaling cascades that influence a range of immune cells that are important in common and unusual illnesses.
